This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (54)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

HERBERT E. KAUFMAN, M.D.; EEVA-LIISA MARTOLA, M.D.; CLAES H. DOHLMAN, M.D.

Arch Ophthalmol. 1963;69(4):468-472.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The use of corticosteroids in the treatment of infection by herpes simplex has been a subject of great controversy. Several articles have been written on the value of corticosteroids, especially in metaherpetic or disciform keratitis and in cases with herpetic iritis.^1,2 On the other hand, even in patients with disciform disease and iritis, corticosteroids have been shown to cause recurrences of superficial corneal lesions and perforation of the cornea.^3,4 Some authors have condemned their use, even in cases of disciform keratitis, while others, such as DeVoe, feel that the benefits of using corticosteroids in patients with stromal herpes or iritis are so great that such therapy is well worth the risk.^5,6

The agent 5-iodo-2'-deoxyuridine (IDU) inhibits the synthesis of virus, and can successfully treat corneal disease caused by herpes simplex and vaccinia, without damaging normal tissues. It is not a cauterizing or debriding agent, but rather, as . . . [Full Text PDF of this Article]

Author Affiliations
Gainesville, Fla.; Boston

Footnotes
Submitted for publication Oct. 18, 1962.

This work was supported in part by U.S. Public Health Service Grants B3538 and B2220 from the National Institute of Neurological Diseases and Blindness of the National Institutes of Health.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?